Trials / Terminated
TerminatedNCT00831649
A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of natalizumab in subjects with active rheumatoid arthritis (RA) receiving concomitant methotrexate (MTX)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | natalizumab |
Timeline
- Start date
- 2004-09-01
- Primary completion
- 2005-02-01
- First posted
- 2009-01-29
- Last updated
- 2016-06-16
Source: ClinicalTrials.gov record NCT00831649. Inclusion in this directory is not an endorsement.